INTECH MEDICAL acquired by MONTAGU PRIVATE EQUITY

Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market

The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform

Orkla completed its acquisition of NutraQ to strategically enhance its presence in high-growth market segments, specifically the health category and the direct-to-consumer (D2C) channel. The transaction provides Orkla with a new, subscription-based business model, diversifying its traditional go-to-market strategies and offering exciting growth opportunities

Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery

Naxicap Partners acquired a majority stake (~80%) in Groupe Lagarrigue from Ardian and iXO Private Equity. The management team reinvested to hold the remaining ~20%. Naxicap prevailed in a competitive auction process managed by Edmond de Rothschild Corporate Finance, beating out offers from IK Investment Partners and Cobepa

DiaSorin has finalized the acquisition of Luminex Corporation, an operation designed to fundamentally strengthen the group’s competitive positioning within the molecular diagnostics and life sciences sectors

CVC acquired a majority stake in Cooper-Vemedia from Charterhouse. The transaction, valued at EUR2.2 billion, was won in a competitive process against a PAI/Ontario Teachers' consortium. The acquisition reflects CVC's appetite for high-cash-flow businesses with low capital intensity (Capex ~EUR10M)

Siparex ETI has entered into exclusive negotiations to acquire a majority stake in Winncare, marking the first investment of its Siparex ETI 5 fund. This transaction follows a successful period of ownership by IDI, which originally took control of the group in 2014 and supported a doubling of the company,s size through international expansion

For the first time since its founding in 1913, Proteor has opened its capital to institutional investors through a primary Owner Buy-Out (OBO). Ardian Growth and BNP Paribas Développement have injected €24 million (a mix of convertible bonds and equity) to support the group's next phase of expansion

Montagu Private Equity entered into exclusive negotiations to acquire a majority stake in IMV Technologies from Qualium Investissement. Montagu prevailed in a competitive process against CVC Capital Partners